drugset
drugset / Trial / NCT03367715

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

NCT03367715 ↗

Phase 2 Completed 10 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.

Timeline

Start
2018-02-07
Primary completion
2021-05-20
Completion
2022-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 1 mg/kg —
Subject Nivolumab Monoclonal antibody 3 mg/kg —

Indications

glioblastoma